Why does DBVT lag the market?
Up 6% over three years while the S&P 500 rose 58%.
- It filed a prospectus for an at-the-market program for new shares on Sep 5, 2025; free cash flow went from -$56.4M to -$121.7M.
−2Long-term trend
DBVT's Quality Score rose 1 point on Fri, Nov 20, to -7. Trading was quieter than usual.
Follow DBVT's trial news. Pro members can get an alert when DBV Technologies files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 6% over three years while the S&P 500 rose 58%.
−2Long-term trend
| Since its 2022 high | Down 71% |
| Latest filing | 8-K, Oct 28 |
After its last 4 reports it closed -2.7% on average, higher 0 of 4 times.
About 3 quarters
No shelf registration or at-the-market program on file in the last three years.
Chief Medical Officer Pharis Mohideen sold 464 shares on Jul 29. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
DBVT is #227 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 227 |
Expected to report Thu Mar 25, after the close (in 124 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Net cash used in operating & investing activities was $159.4 million for the nine months ended September 30, 2026, compared to $86.7 million for the nine months ended September 30, 2025, reflecting the continued advancement of these activities and the expansion of the Company's organization.”
DBVT's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | -12.2% | -3.4% | -6.7% |
| Jul 16, 2026 | +1.3% | -1.1% | -6.7% |
| Apr 30, 2026 | +0.9% | -5.4% | -4.8% |
Sales grew in two of the last six years, to $5.6M in 2025. It made a profit in two of the seven years.
RSI 37.7, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
“The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid change as researchers learn more about diseases and develop new technologies and treatments.”
DBVT scores -7 today, which Breakaway calls Poor. It is #227 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 6% over three years while the S&P 500 rose 58%. Cash lasts about 3 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
DBVT scores -7 today, which Breakaway calls Poor (below zero). That is #227 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DBVT's -7.
Expected to report Thu Mar 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DBVT closed higher after 0 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.